Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals will present new clinical and real-world data at the AHA Scientific Sessions 2026 and ISA 2026. The presentations will focus on the benefits of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). These events are set to take place in November 2026 in Chicago and Montevideo.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alnylam to present new clinical data at AHA and ISA 2026.
  • Evidence supports benefits of RNAi-powered TTR silencing.
  • Presentations scheduled for major scientific events.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Lead asset
ALN-4324
Phase 2 · Type 2 Diabetes Mellitus (T2DM)

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18 in Montevideo, Uruguay. The presentations add to the growing body of evidence demonstrating strength in RNAi

Frequently Asked Questions

What data will Alnylam present at AHA 2026?

Alnylam will present new clinical and real-world data on RNAi-powered TTR silencing.

When are the AHA and ISA 2026 events?

The AHA event is from November 6-9, and ISA is from November 15-18, 2026.

Where will the ISA 2026 take place?

The ISA 2026 will be held in Montevideo, Uruguay.

What is AMVUTTRA®?

AMVUTTRA® (vutrisiran) is an RNAi therapeutic for TTR silencing.

ShareAdd on Google
Tags: ALNY Alnylam RNAi TTR silencing AMVUTTRA HELIOS-B
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$3587M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 2
Type 2 Diabetes Mellitus (T2DM) →

Catalyst track record

+13%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →